LINEAGE CELL THERAPEUTICS IN

Lineage Cell’s new insider option deals signal executive confidence and a bullish outlook for cell‑therapy growth—watch upcoming FDA milestones for upside.

Lineage Cell Therapeutics’ insider option purchases reveal executive confidence in its precision‑medicine pipeline, signaling potential upside amid R&D‑heavy growth.